BioCryst Pharmaceuticals Backs ORLADEYO Outlook as Navenibart Trial Advances
BioCryst said it expects ORLADEYO to reach $1B peak sales, citing payer mix of ~60% commercial, 20% Medicare Part D and 20% Medicaid and gross-to-net around 15% last year. Pediatric ORLADEYO launch was delayed by a batch manufacturing issue, not safety-related. In Phase 3, navenibart ALPHA-ORBIT enrollment should finish by end-June; top-line data due Q3 next year, with a likely 2H 2028 launch. BioCryst reported pro forma cash of $330M and expects profitability this year and next.
Near-term ORLADEYO supply/timing risk is partially offset by continued pediatric prescription momentum and reiterated navenibart development milestones.
BioCryst said pediatric ORLADEYO launch is delayed by a batch manufacturing issue and expects to resume manufacturing soon.
Shares may see choppy trading on the pediatric launch delay, but downside could be limited by the reaffirmed Phase 3 enrollment timeline and 2027 filing/2028 launch expectations.
Background
BioCryst is commercializing ORLADEYO (berotralstat) for hereditary angioedema and running Phase 3 for navenibart (kallikrein inhibitor) while developing BCX17725 for Netherton syndrome.
Why it matters
The newest actionable items are (1) a batch-specific manufacturing issue delaying pediatric ORLADEYO launch, and (2) updated Phase 3 enrollment completion timing and expected top-line readouts/filing window for navenibart.
Market relevance
Traders get near-term execution risk (pediatric launch timing) plus longer-dated catalysts (Phase 3 cadence and potential BLA filing/launch window).
Market effects
Reinforces investor focus on oral HAE prophylaxis execution risk (manufacturing readiness) alongside late-stage trial cadence.
Limited; primarily US biotech sentiment and rare-disease pharma expectations.
Moderate; ORLADEYO is US/EU commercial, but the disclosed issue is described as batch-specific manufacturing timing.
Alternative perspectives
The pediatric delay could be more than a short-term blip if pharmacy stocking slips further, and the article doesn’t quantify the duration or exact ship date.
Modeling assumptions hinge on ORLADEYO staying on-therapy and on navenibart’s competitive positioning vs. oral and injectable rivals; any uptake friction could pressure peak-sales confidence.
Key entities
- productORLADEYO
BioCryst’s oral kallikrein inhibitor; pediatric launch delayed due to a batch-specific manufacturing issue.
- clinical_programnavenibart
Phase 3 ALPHA-ORBIT trial; enrollment expected to finish by end of June, with top-line data expected in Q3 next year.
- clinical_programBCX17725
Netherton syndrome program; data from 12 patients through three months expected by year-end.
